- Trials with a EudraCT protocol (81)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
81 result(s) found for: Glucose uptake.
Displaying page 1 of 5.
EudraCT Number: 2004-004215-35 | Sponsor Protocol Number: TENPET | Start Date*: 2005-01-19 |
Sponsor Name:Turku PET Centre | ||
Full Title: Influence of muscle specific activation on regional glucose uptake in the human Achilles tendon | ||
Medical condition: The combined forces generated by the triceps surae muscles causes non-uniform strain within the human triceps aponeuroses. This may cause non-uniform tendon force that would result in intratendinou... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000731-31 | Sponsor Protocol Number: NL76746.068.21 | Start Date*: 2021-10-14 |
Sponsor Name:Maastricht University | ||
Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans | ||
Medical condition: Type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001663-22 | Sponsor Protocol Number: na | Start Date*: 2018-09-05 |
Sponsor Name:Maastricht University | ||
Full Title: Effects of ciprofibrate on myocardial insulin sensitivity in pre-diabetes | ||
Medical condition: Insulin resistance, diastolic cardiac failure, mitochondrial function | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000404-35 | Sponsor Protocol Number: 80519 | Start Date*: 2022-07-26 |
Sponsor Name:AMC, Cardiovascular Sciences | ||
Full Title: Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes? | ||
Medical condition: Inflammation in patients with type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004245-16 | Sponsor Protocol Number: NL67646.068.18 | Start Date*: 2019-04-16 |
Sponsor Name:Maastricht University | ||
Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002373-35 | Sponsor Protocol Number: T153/2016 | Start Date*: 2016-07-04 |
Sponsor Name: | ||
Full Title: The Effects of Dietary Peptides on Human Brown Adipose Tissue | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002094-38 | Sponsor Protocol Number: 0584 | Start Date*: 2016-12-29 |
Sponsor Name:University of Leicester | ||
Full Title: The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in people with absolute or relative endogenous insulin deficiency | ||
Medical condition: Type 1 and Type 3c diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2007-003921-25 | Sponsor Protocol Number: 111222 | Start Date*: 2009-07-27 | |||||||||||
Sponsor Name:Västra Götalandsregionen | |||||||||||||
Full Title: The effect of selective PDE-5 inhibition on capillary recruitment, glucose uptake and endothelial function following a mixed meal in patients with type 2 diabetes | |||||||||||||
Medical condition: Our primary objective is to elucidate whether increase in cGMP mediated by acute administration of tadalafil, a selective well tolerated PDE-5 inhibitor, may affect capillary recruitment and muscle... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001733-86 | Sponsor Protocol Number: 1710 | Start Date*: 2014-10-15 |
Sponsor Name:Maastricht University | ||
Full Title: The effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects | ||
Medical condition: Obesity, glucose intolerance, endothelial dysfunction | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004059-34 | Sponsor Protocol Number: C7Q040 | Start Date*: 2021-02-25 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Stimulation of the beta-2 adrenergic receptor for activating human brown adipose tissue | |||||||||||||
Medical condition: Obesity, overweight, lipid- and glucose metabolism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003676-39 | Sponsor Protocol Number: 109147 | Start Date*: 2021-07-20 |
Sponsor Name: | ||
Full Title: Effects of sodium lactate infusion in patients with glucose transporter 1 deficiency syndrome (GLUT1DS) | ||
Medical condition: In glucose transporter 1 deficiency syndrome (GLUT1DS) cerebral glucose uptake from the systemic blood circulation is limited, because of deficient transport of glucose across the blood-brain barri... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017587-16 | Sponsor Protocol Number: 006117 | Start Date*: 2010-12-02 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: Treatment monitoring using FDG-PET/CT and FLT-PET/CT in patients with Hodgkin Lymphoma. | ||
Medical condition: Hodgkin Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-004637-27 | Sponsor Protocol Number: AZ-01_SGLT-2 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Medizinische Universität Graz | |||||||||||||
Full Title: A randomized, double-blind, three arm, three treatment period, cross-over trial to investi-gate the effect of a SGLT-2 inhibitor, a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on gluca... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003566-13 | Sponsor Protocol Number: GLP1-hypofyse | Start Date*: 2019-01-02 |
Sponsor Name:Radboud university medical center | ||
Full Title: iPAVE – imaging Pituitary ActiVation by Exendin | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000619-10 | Sponsor Protocol Number: RUNMC-EX-BCM-2012 | Start Date*: 2012-07-24 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||||||||||||
Full Title: Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4 | ||||||||||||||||||||||||||||
Medical condition: patients with long-standing type 1 diabetes | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001557-29 | Sponsor Protocol Number: A2171035 | Start Date*: 2006-11-24 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJE... | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) FI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000821-35 | Sponsor Protocol Number: RUNMC-GLP1-TRANSPL-2015 | Start Date*: 2015-09-22 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Visualizing beta cells after Intrahepatic Islet of Langerhans Transplantation | ||||||||||||||||||||||||||||
Medical condition: Intrahepatic islet transplantation in type 1 diabetes patients | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002712-51 | Sponsor Protocol Number: 2020 | Start Date*: 2021-03-05 | |||||||||||
Sponsor Name:Kirsi Pietiläinen | |||||||||||||
Full Title: Semaglutide as an adjunct to dieting in the treatment of type 2 diabetes – effects on glucose metabolism, prevention of weight regain and peripheral tissue metabolic activation | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002643-28 | Sponsor Protocol Number: CA209-8JD | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. | |||||||||||||
Medical condition: Stage III/IV resectable oral squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001381-96 | Sponsor Protocol Number: LG_T1_EGP | Start Date*: 2014-06-17 |
Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel | ||
Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept... | ||
Medical condition: Diabetes Mellitus Type 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
